Ginan Biomedics is a subsidiary of BLT, and represents the scientific and technical foundation behind the development of kangaroo‑derived Xeno:K implants.

The name Ginan is drawn from Australian Indigenous culture, referring to a star within the Southern Cross constellation that is understood as a dilly bag holding important songs and knowledge. The name reflects the idea of knowledge being held, protected, and carried forward - a name that reflects the role Ginan plays within the BLT group.

Within the BLT group, teams operating under the Ginan name contribute to product development and pilot‑scale manufacturing activities that support the translation of kangaroo tissues into regulated medical devices. These activities are undertaken as part of a broader, integrated development program led by BLT and are aligned with the group’s commercialisation and clinical objectives.

BLT serves as the primary operating brand, while Ginan reflects the accumulated knowledge, intellectual property, and translational capability that underpin the group’s technology platform.

Together, BLT and Ginan are progressing kangaroo tissue‑based medical technologies toward clinical and commercial application.